Efficacy and Toxicity of Factor Xa Inhibitors - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Pharmacy and Pharmaceutical Sciences Année : 2013

Efficacy and Toxicity of Factor Xa Inhibitors

Résumé

Venous thromboembolism (VTE) is a serious disease that is often neglected, and effective and safe antithrombotic treatments are a public health priority. New antithrombotics such as rivaroxaban, apixaban, betrixaban, edoxaban, darexaban, TAK-442, LY517717, eribaxaban, otamixaban are being developed to overcome current therapeutic limitations. The new oral anticoagulants and parenteral otamixaban are under evaluation in clinical trials for VTE treatment, for VTE prevention in orthopedic surgery, for stroke prevention in patients with atrial fibrillation and for cardiovascular event prevention in patients with acute coronary syndrome. These antithrombotic agents directly and selectively inhibit factor Xa, and do not require coagulation monitoring and dose adjustment. Several of these drugs have shown promising results and have the potential to either replace or act as alternatives to traditional anticoagulants (heparins, vitamin K antagonists).
Fichier principal
Vignette du fichier
JPPS-2013.pdf (409.14 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-01423391 , version 1 (29-12-2016)

Identifiants

Citer

Maryna Bondarenko, Christophe Curti, Marc Montana, Pascal Rathelot, Patrice Vanelle. Efficacy and Toxicity of Factor Xa Inhibitors. Journal of Pharmacy and Pharmaceutical Sciences, 2013, 16, pp.74 - 88. ⟨10.18433/J33P49⟩. ⟨hal-01423391⟩
138 Consultations
170 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More